Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism

Fontana, Pierre; Goldhaber, Samuel Z; Bounameaux, Henri

doi:10.1093/eurheartj/ehu027

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism
Authors		Fontana, Pierre Goldhaber, Samuel Z Bounameaux, Henri
Published in		European heart journal. 2014, vol. 35, no. 28, p. 1836-1843
Abstract		Direct oral anticoagulants (DOACs) specifically target factor IIa or Xa and represent a major step forward in the treatment of acute- and long-term prevention of venous thrombo-embolism (VTE). They are at least as effective and as safe as conventional therapy (heparins and vitamin-K inhibitors) and have practical advantages, such as fixed dosing and no need for laboratory monitoring. These antithrombotic agents introduce a new paradigm for the day-to-day management of VTE. Direct oral anticoagulants should streamline the management of most patients with VTE and will facilitate care in the outpatient setting. Nevertheless, it remains uncertain how to select specific DOACs for particular profiles of patients, and the optimal management of bleeding complications is evolving.
Identifiers		DOI: 10.1093/eurheartj/ehu027 PMID: 24510637
Full text		Article (Published version) (309 Kb) - Free access
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine
Research groups		Geneva Platelet Group (13) La maladie thromboembolique veineuse (808)
Citation (ISO format)		FONTANA, Pierre, GOLDHABER, Samuel Z, BOUNAMEAUX, Henri. Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. In: European Heart Journal, 2014, vol. 35, n° 28, p. 1836-1843. doi: 10.1093/eurheartj/ehu027 https://archive-ouverte.unige.ch/unige:34829